Rize Oncology Inc.
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 41.89% | 7.71% | -50.94% | -56.05% | -32.25% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,234.29% | -80.11% | -3.30% | 1,057.89% | -109.45% |
| Change in Net Operating Assets | -251.43% | 9,871.43% | 100.62% | -253.76% | 146.13% |
| Cash from Operations | 95.58% | 22.47% | -6.36% | -263.43% | -25.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -93.69% | -73.88% | 2,600.00% | 96.77% | -478.42% |
| Miscellaneous Cash Flow Adjustments | 100.00% | -- | -- | -- | -- |
| Net Change in Cash | 163.08% | 9.29% | 5.92% | -284.53% | 400.92% |